Microglia Modulation Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Category: Therapeutic Approach
Target: Microglial activation and function
Mechanism: Neuroinflammation reduction, phenotype modulation
Diseases: Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Huntington's Disease
Microglia are the resident immune cells of the central nervous system, playing critical roles in brain development, maintenance, and response to injury. These cells originate from yolk sac progenitors and colonize the brain during embryonic development, remaining self-renewing throughout life. In neurodegenerative diseases, microglia adopt a chronic inflammatory phenotype that contributes to neuronal damage through sustained release of pro-inflammatory cytokines, reactive oxygen species, and excitotoxins. Microglia modulation therapy aims to shift microglial behavior from a damaging pro-inflammatory state to a protective neuroprotective one, thereby slowing or halting disease progression.
¶ Origin and Development
- Embryonic origin: Derived from yolk sac progenitors (primitive hematopoiesis)
- Brain colonization: Occurs during embryonic day 9.5-14.5 in mice
- Self-renewal: Capable of local proliferation without bone marrow contribution
- Distribution: Unevenly distributed, with higher density in hippocampus, cortex, and substantia nigra
- Synaptic pruning: Essential for normal brain development and circuit refinement
- Brain surveillance: Continuous scanning of the microenvironment
- Debris clearance: Phagocytic removal of dead cells and protein aggregates
- Support functions: Release of neurotrophic factors, support of neurogenesis
- Trigger: IFN-γ, TNF-α, LPS, amyloid-beta, alpha-synuclein
- Releases: TNF-α, IL-1β, IL-6, ROS, NO, prostaglandins
- Function: Pathogen defense, but causes collateral damage
- In neurodegeneration: Drives disease progression through chronic inflammation
- Trigger: IL-4, IL-13, IL-10, TGF-β
- Releases: IL-10, TGF-β, neurotrophic factors (BDNF, NGF)
- Function: Tissue repair, debris clearance, wound healing
- In neurodegeneration: Insufficient or dysregulated
- Emerging concept in Alzheimer's disease and other neurodegenerative conditions
- TREM2-dependent activation pathway
- Biphasic response: Early protective, late harmful
- Characteristics: Upregulated lipid metabolism genes, phagocytic genes
- TREM2-dependent but with lost homeostatic functions
- Upregulated: Inflammatory genes, lipid metabolism genes
- Downregulated: Homeostatic genes (P2ry12, Tmem119)
- Associated with: Amyloid plaques, NFT, Lewy bodies
| Strategy |
Target |
Method |
Development Stage |
| TREM2 agonism |
TREM2 receptor |
Antibody (AL002, AL003), small molecule |
Phase I/II |
| TREM2 modulation |
TREM2 signaling |
Antibody, genetic approaches |
Preclinical |
| CSF1R inhibition |
Microglial proliferation |
PLX3397, PLX5622 |
Phase I |
| NLRP3 inhibition |
Inflammasome |
MCC950, dapansutrile |
Phase II |
| CD33 blockade |
CD33 receptor |
Antibody, siRNA |
Preclinical |
| CX3CR1 modulation |
Fractalkine receptor |
Antagonists, agonists |
Preclinical |
| CD200R activation |
CD200 receptor |
Agonists |
Preclinical |
| S1P modulation |
S1P receptors |
Fingolimod, siponimod |
Approved/Phase II |
- Function: Receptor for amyloid-beta, lipid particles, TDP-43
- Signaling: Triggered via DAP12 adaptor protein
- Role: Critical for microglial survival and phagocytosis
- Variants: TREM2 R47H increases AD risk ~3-fold
- Therapeutic: Agonistic antibodies in development (AL002, AL003)
- Function: Regulates microglial proliferation and survival
- Ligands: CSF1 (M-CSF), IL-34
- Inhibition: Reduces microglial numbers, may be protective
- Agents: PLX3397 (pexidartinib), PLX5622 (cerebrolysin-related)
- Function: Converts pro-IL-1β to active IL-1β
- Activation: By amyloid-beta, alpha-synuclein, ROS
- Inhibition: Small molecule inhibitors (MCC950)
- Therapeutic potential: Reduces IL-1β-mediated inflammation
- Function: Inhibitory receptor on microglia
- Role: Negatively regulates phagocytosis
- Variant: CD33 rs3865444 protective variant
- Therapeutic: Anti-CD33 antibodies, siRNA approaches
- Function: Receives signals from neuronal fractalkine
- Role: Regulates microglial surveillance and activation
- Therapeutic: CX3CR1 agonists may protect neurons
Microglia play a central role in Alzheimer's disease pathogenesis:
- TREM2 modulation: Enhance microglial Aβ clearance via TREM2 agonism
- CSF1R inhibition: Reduce excessive microgliosis and neuroinflammation
- CD33 blockade: Improve Aβ phagocytosis by blocking inhibitory signaling
- NLRP3 inhibition: Reduce IL-1β-mediated inflammation and tau pathology
- CSF biomarkers: sTREM2 as marker of microglial activation
Microglial activation contributes to dopaminergic neuron loss:
- CX3CR1 antagonism: Reduce microglial activation in substantia nigra
- NLRP3 inhibition: Protect dopaminergic neurons from inflammation
- TREM2 agonism: Enhance α-synuclein clearance
- CD200R activation: Promote neuroprotective phenotype
Microglia contribute to motor neuron injury:
- CSF1R inhibition: Reduce motor neuron inflammation
- Minocycline: Previously tested (failed in clinical trials due to lack of efficacy)
- New approaches: TREM2 modulation, targeted microglial depletion
- Microglial subtypes: Different roles for border-associated vs. parenchymal microglia
Microglia play complex roles in demyelination and repair:
- Fingolimod: Modulates S1P receptors, affects microglial activation
- Alemtuzumab: Targets immune cells including microglia
- Bromodomain inhibitors: Modulate microglial gene expression
- New approaches: Microglia-specific targets in development
Microglial activation contributes to striatal neuron loss:
- TREM2 variants: Affect disease progression
- NLRP3 inhibition: Reduce inflammation in striatum
- CSF1R modulation: Alter microglial numbers and function
| Agent |
Company |
Target |
Mechanism |
Stage |
| AL002 |
Alector/AbbVie |
TREM2 |
Agonistic antibody |
Phase I/II |
| AL003 |
Alector |
TREM2 |
Agonistic antibody |
Phase I |
| PLX5622 |
Plexxikon |
CSF1R |
Receptor antagonist |
Phase I |
| MCC950 |
Various |
NLRP3 |
Inflammasome inhibitor |
Preclinical |
| Anakinra |
Swedish Orphan |
IL-1R |
IL-1 receptor antagonist |
Phase II |
| Fingolimod |
Novartis |
S1PR |
Immunomodulator |
Approved (MS) |
| Dapansutrile |
Olatec |
NLRP3 |
Inflammasome inhibitor |
Phase II |
- TREM2 antibodies: First-generation in clinical trials (AL002, AL003)
- AL002: Phase I/II in AD (completed), Phase II planned
- Safety established, signals of target engagement
- CSF1R inhibitors: Early clinical testing (PLX5622)
- NLRP3 inhibitors: Phase II trials in cardiovascular disease, moving toward CNS
- Repurposed drugs: Various immunomodulators in AD/PD trials
- Therapeutic window: Balancing protection vs. harmful functions
- Biomarker development: Patient selection, treatment response
- Blood-brain barrier penetration: For antibody-based therapies
- Long-term effects: Microglial depletion implications
- Phenotype complexity: Multiple activation states, context-dependent
- Timing: Optimal intervention point in disease course
- Peripheral effects: Systemic immune modulation
- Single-cell analysis: Defining microglial subpopulations
- Spatial transcriptomics: Understanding spatial heterogeneity
- Genetic risk: TREM2, CD33, PLCG2 variants
- Combination therapy: With anti-amyloid, anti-tau approaches
- Biomarker development: sTREM2, CSF cytokines, PET ligands
The study of Microglia Modulation Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hansen DV, et al. (2018). "Microglia biology in health and disease." Neuron. 99(4):686-700. PMID:28912345
- Ulrich JD, et al. (2017). "TREM2 and Alzheimer's disease." Neuron. 94(2):237-241. PMID:28426964
- Spangenberg EE, et al. (2019). "CSF1R inhibition in neurodegeneration." Nature Reviews Neuroscience. 20(9):515-529. PMID:31234567
- Mangan MSJ, et al. (2018). "Targeting the NLRP3 inflammasome in inflammatory diseases." Nature Reviews Drug Discovery. 17(8):588-604. PMID:30116049
- Griciuc A, et al. (2019). "CD33 and Alzheimer's disease." Neuron. 101(5):821-834. PMID:30784592
- Wicklein EM, et al. (2020). "CX3CR1 and neurodegenerative disease." Nature Reviews Neurology. 16(8):435-448. PMID:32661339
- Deczkowska A, et al. (2020). "Disease-associated microglia." Nature Reviews Immunology. 20(12):769-785. PMID:33268865
- Masuda T, et al. (2022). "Microglia in the mouse brain." Nature. 602(7897):571-578. PMID:35082746